147 related articles for article (PubMed ID: 11842389)
1. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P
Semin Oncol; 2002 Feb; 29(1 Suppl 2):48-55. PubMed ID: 11842389
[TBL] [Abstract][Full Text] [Related]
2. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P
Semin Oncol; 2002 Feb; 29(1S2):48-55. PubMed ID: 28140092
[TBL] [Abstract][Full Text] [Related]
3. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
[TBL] [Abstract][Full Text] [Related]
4. The role of mitoxantrone in the treatment of indolent lymphomas.
Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
McLaughlin P; Estey E; Glassman A; Romaguera J; Samaniego F; Ayala A; Hayes K; Maddox AM; Preti HA; Hagemeister FB
Blood; 2005 Jun; 105(12):4573-5. PubMed ID: 15741224
[TBL] [Abstract][Full Text] [Related]
6. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
Nastoupil LJ; McLaughlin P; Feng L; Neelapu SS; Samaniego F; Hagemeister FB; Ayala A; Romaguera JE; Goy AH; Neal E; Wang M; Fayad L; Fanale MA; Oki Y; Westin JR; Rodriguez MA; Cabanillas F; Fowler NH
Br J Haematol; 2017 Apr; 177(2):263-270. PubMed ID: 28340281
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Zinzani PL; Pellegrini C; Broccoli A; Gandolfi L; Stefoni V; Casadei B; Maglie R; Argnani L; Pileri S
Hematol Oncol; 2015 Sep; 33(3):141-6. PubMed ID: 24986783
[TBL] [Abstract][Full Text] [Related]
9. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients.
Hirt C; Schüler F; Kiefer T; Schwenke C; Haas A; Niederwieser D; Neser S; Assmann M; Srock S; Rohrberg R; Dachselt K; Leithäuser M; Rabkin CS; Herold M; Dölken G
Br J Haematol; 2008 May; 141(5):631-40. PubMed ID: 18422779
[TBL] [Abstract][Full Text] [Related]
10. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE
Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734
[TBL] [Abstract][Full Text] [Related]
11. Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphoma.
Tsimberidou AM; Jiang Y; Ford RJ; Lichtiger B; Medeiros LJ; McLaughlin P; Cabanillas F; Sarris AH
Leuk Lymphoma; 2002 Aug; 43(8):1589-98. PubMed ID: 12400601
[TBL] [Abstract][Full Text] [Related]
12. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.
Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R
Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339
[TBL] [Abstract][Full Text] [Related]
13. Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Hiddemann W; Dreyling M; Unterhalt M
Semin Oncol; 2003 Feb; 30(1 Suppl 2):16-20. PubMed ID: 12652460
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
15. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.
Ma SY; Au WY; Chim CS; Lie AK; Lam CC; Tse E; Leung AY; Liang R; Kwong YL
Br J Haematol; 2004 Mar; 124(6):754-61. PubMed ID: 15009063
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
Czuczman MS; Koryzna A; Mohr A; Stewart C; Donohue K; Blumenson L; Bernstein ZP; McCarthy P; Alam A; Hernandez-Ilizaliturri F; Skipper M; Brown K; Chanan-Khan A; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-Lopez A; Bernstein SH
J Clin Oncol; 2005 Feb; 23(4):694-704. PubMed ID: 15681517
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
[TBL] [Abstract][Full Text] [Related]
20. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.
Czuczman MS
Semin Oncol; 1999 Oct; 26(5 Suppl 14):88-96. PubMed ID: 10561023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]